Adherence of patients with schizophrenia to hypothyroidism treatment Authors: Shay Gur, Shira Weizman, Haggai Hermesh, Andre Matalon, Joseph Meyerovitch, Amir Krivoy, Shay Gur, Shay Gur Published: 2023 ABSTRACT Adherence to prescription medications is critical for both remission from schizophrenia and control of physical comorbidities. While schizophrenia with comorbid hypothyroidism is common, there is little research on adherence to hypothyroidism treatment in this population. The current study used a retrospective, matched case-control design. The cohort included 1,252 patients diagnosed with schizophrenia according to ICD-10 and 3,756 controls matched for gender, age, socioeconomic status and ethnicity without diagnosis of schizophrenia. All data were retrieved from the electronic medical database of a large health maintenance organization. Retrieved data included demographics, thyroid functionality test results and prescribed medications. Measures of adherence to therapy were used for analyses as were data from follow-ups of patients with hypothyroidism. A diagnosis of hypothyroidism was found in 299 patients, 115 of whom were also diagnosed with schizophrenia. The 184 without schizophrenia constituted the control group. No statistically significant differences were found between the two groups regarding prescriptions for L-thyroxin and TSH levels and number of TSH tests. Adherence of patients with schizophrenia to hypothyroidism treatment was found to be as good as that of individuals without a schizophrenia diagnosis. Impact statement Our results show that psychiatric patients, unlike their adherence to psychotropic agents, adhere very well to their physical illnesses medication regime in this study. Caretakers should therefore change their stigmatizing attitude toward patients with schizophrenia with regard to adherence to hypothyroidism treatment and offer them the same level of care as is offered to patients with no mental health issues. Introduction Schizophrenia is a chronic mental disorder with a worldwide prevalence of about 1% (Rössler et al., 2005). Illness course involves recurrent psychotic exacerbations interrupted by periods of remission with “negative” symptoms, and impairment in functionality increases gradually. Psychotic symptoms usually respond to antipsychotic medications, which are also used for long-term maintenance and prevention (Kane and Correll, 2019). Yet, according to research, due to a multitude of factors, 34–81% of patients discontinue their antipsychotic medications with many studies putting the rate around 50% (Yang et al., 2012; El-Mallakh and Findlay, 2015; García et al., 2016; Lafeuille et al., 2016; Bright, 2017; De Las Cuevas et al., 2017; Velligan et al., 2017). In the general population, non-adherence to prescribed medications is a common obstacle to effective treatment of many chronic physical disorders, with rates of non-adherence reported to be 43–78% (Osterberg and Blaschke, 2005). Reasons for non-adherence like economic difficulties, lack of awareness of the importance of treatment for the illness, cognitive deficits and poor provider–patient relationship are even more common in patients with schizophrenia (Osterberg and Blaschke, 2005). Stigma-motivated underestimation of patients’ ability to cooperate is often involved and may lead physicians to assume that deterioration of a chronic physical disorder in a patient with schizophrenia is due to non-adherence to treatment, thus causing the physicians to refrain from searching for non-mental health-related sources of the deterioration. Some early studies on patients with schizophrenia pointed to a trend toward lower adherence rates to prescribed medications, relative to the general population. These findings, however, were later attributed to the fact that the methods used for estimating adherence were incorrect (Cramer and Rosenheck, 1998). More recent research has shown that patients with schizophrenia have equal or better adherence rates to antidiabetics (Dolder et al., 2003; Simard et al., 2015; Gorczynski et al., 2017), antihypertensives (Dolder et al., 2003; Dolder et al., 2005; Siegel et al., 2007) and antihyperlipidemics (Dolder et al., 2003; Owen-Smith et al., 2016). Additionally, while mental illness, including schizophrenia, has been found to correlate with diagnostic and primary treatment delays in patients with breast cancer, most patients who initiate endocrine therapies adhere to the treatment no less than the general population (Iglay et al., 2017). Some studies have found a correlation between adherence to antipsychotic medications and adherence to medications prescribed for physical disorders (Hansen et al., 2012; Shafrin et al., 2019). Thus, one may assume that a patient adhering to antipsychotics will also adhere to other medications. Previous research has shown that there is an increased rate of hypothyroidism in patients with schizophrenia (Melamed et al., 2020). Some studies suggest an association between disorders of the thyroid hormone and mental disorders (Bono et al., 2004; Davis and Tremont, 2007; Radhakrishnan et al., 2013; Remaud et al., 2014; Samuels, 2014). A South Korean study has found that the prevalence of hypothyroidism among schizophrenia patients is 4.9% (Park et al., 2021). A large US study has found that schizophrenia is associated with hypothyroidism (OR 1.88, 95% CI 1.51–2.32) as well as other substantial chronic medical burdens (Carney et al., 2006). A large-scale Israeli study has found a higher proportion of patients with hypothyroidism among schizophrenia patients than in a control group (2.01% vs. 1.25%, respectively, p < 0.0001), after adjusting for age, gender and smoking status. They, furthermore, found a robust independent association between schizophrenia and hypothyroidism (OR 1.62, p ≤ 0.001) when performing a multivariate logistic regression analysis (Sharif et al., 2018). Three studies have found that the rate of hypothyroidism seems to rise significantly following a diagnosis of schizophrenia (Telo et al., 2016; Melamed et al., 2020; Launders et al., 2022). These observations indicate that chronic antipsychotic treatment may suppress thyroid functioning (Melamed et al., 2020). Non-adherence is a known problem in the management of hypothyroidism, with rates of non-adherence reaching 52% (Hepp et al., 2018), but to the best of our knowledge, our current study is the first to compare adherence to treatment and management of hypothyroidism in patients with schizophrenia to that of the general population suffering from this common endocrine disorder. Methods We examined the medical files of 1,252 adult patients with schizophrenia receiving treatment in the regional clinics of a large HMO in Israel, during the years 2005–2013, and of 3,756 control subjects without any mental disorder – matched for age, gender and socioeconomic status – being treated for physical health issues during the same period. These parameters were included in the model as they may affect the dependent variables. Only those under long-term (at least 5 years) care of a healthcare provider, above 18 years of age and residing in the same urban area in central Israel were included. The predefined ratio of patients to controls was 1:3. The relevant data were collected from the electronic medical database and transferred anonymously to a file, which constituted the data source for the current study. Diagnosis of schizophrenia had been done by senior psychiatrists according to ICD-10 criteria. Exclusion criteria consisted of treatment with clozapine, which represents treatment-resistant schizophrenia, malignancy and organic brain syndrome. The records of individuals with these medical conditions were not retrieved. Among the retrieved records, 121 patients were identified with schizophrenia and comorbid hypothyroidism and 190 controls without schizophrenia but with a registered diagnosis of hypothyroidism. Those were included in our study. Adherence to hypothyroidism treatment was assessed by the following measures:Average annual number of prescriptions of L-thyroxine (a replacement therapy for hormone deficiency in hypothyroid state).Average annual number of serum thyroid stimulating hormone (TSH) level tests, which is a commonly used test for hypothyroidism.Each participant’s average TSH level, which is a measure of treatment success. Average annual number of prescriptions of L-thyroxine (a replacement therapy for hormone deficiency in hypothyroid state). Average annual number of prescriptions of L-thyroxine (a replacement therapy for hormone deficiency in hypothyroid state). Average annual number of serum thyroid stimulating hormone (TSH) level tests, which is a commonly used test for hypothyroidism. Average annual number of serum thyroid stimulating hormone (TSH) level tests, which is a commonly used test for hypothyroidism. Each participant’s average TSH level, which is a measure of treatment success. Each participant’s average TSH level, which is a measure of treatment success. Due to the retrospective nature of the study, the need for informed consent was waved by the institutional review board of the Geha Mental Health Center in Petah Tikva, Israel. The approval number is 095/2012. Statistical analysis Since all the variables are continuous, we used Student’s t-test to calculate the differences between groups. Results In our sample, 299 patients had a diagnosis of hypothyroidism corroborated by at least one result of serum TSH levels. One hundred and fifteen had a diagnosis of schizophrenia as well. The 184 with no schizophrenia constituted the control group. The measures of adherence defined in this study (average annual number of prescriptions of L-thyroxin, average annual number of TSH level tests and average TSH level) are shown in Table 1. No statistically significant differences between the two groups were found in any of the measures.Table 1.Treatment adherencePatients with schizophrenia (N = 115)Controls (N = 184)Mean ± SDMean ± SD p Before diagnosis TSH tests per year1.33 ± 1.931.17 ± 1.460.707Mean TSH (mIU/L)6.10 ± 6.137.01 ± 6.710.098After diagnosis L-thyroxine prescriptions per year4.17 ± 34.78 ± 6.940.862TSH tests per year1.81 ± 1.262.02 ± 5.90.448First TSH level (mIU/L)5.74 ± 7.737.42 ± 13.580.848Mean TSH level (mIU/L)5.11 ± 5.574.79 ± 5.650.848Mean TSH level last year (mIU/L)4.2 ± 5.373.37 ± 2.890.149Latest TSH level included in the study (mIU/L)4.03 ± 3.433.2 ± 2.790.072 Note: Normal range of TSH is 0.4–4.0 mIU/L. Table 1.Treatment adherencePatients with schizophrenia (N = 115)Controls (N = 184)Mean ± SDMean ± SD p Before diagnosis TSH tests per year1.33 ± 1.931.17 ± 1.460.707Mean TSH (mIU/L)6.10 ± 6.137.01 ± 6.710.098After diagnosis L-thyroxine prescriptions per year4.17 ± 34.78 ± 6.940.862TSH tests per year1.81 ± 1.262.02 ± 5.90.448First TSH level (mIU/L)5.74 ± 7.737.42 ± 13.580.848Mean TSH level (mIU/L)5.11 ± 5.574.79 ± 5.650.848Mean TSH level last year (mIU/L)4.2 ± 5.373.37 ± 2.890.149Latest TSH level included in the study (mIU/L)4.03 ± 3.433.2 ± 2.790.072 Note: Normal range of TSH is 0.4–4.0 mIU/L. Treatment adherence Note: Normal range of TSH is 0.4–4.0 mIU/L. Discussion Several measures used in our study indicated that in patients diagnosed with comorbid schizophrenia and hypothyroidism, the adherence rate to hypothyroidism medications was as good as that of patients with hypothyroidism and no mental disorder. This is in line with previous research on the adherence of patients with schizophrenia and comorbid physical disorders (Dolder et al., 2003; Dolder et al., 2005; Siegel et al., 2007; Simard et al., 2015; Owen-Smith et al., 2016; Gorczynski et al., 2017; Iglay et al., 2017). Studies consistently demonstrated that patients with schizophrenia have higher rates of physical disorders and a shortened lifespan (Dieset et al., 2016; Hjorthøj et al., 2017). This morbidity and mortality gap has been attributed to a variety of factors, including common biological underpinnings (Crawford et al., 2014), medication effects (Pillinger et al., 2020), suicidality (Hor and Taylor, 2010) and non-adherence (Crawford et al., 2014). As mentioned before, the results of our study indicate that non-adherence is not a significant factor in this context. This finding has implications in two main areas. One is the education of clinicians. Such information could help reduce the stigmatic view that patients with schizophrenia cannot be reliable partners in establishing and implementing a treatment plan (Chaudhry et al., 2010; Briskman et al., 2012; Firth et al., 2016). The second area is resource investment. Economic resources intended to help close the morbidity–mortality gap should be directed to other factors mentioned above rather than to treatment adherence of patients with schizophrenia. The findings of the current study clearly show that schizophrenic patients adhere to hypothyroid (and probably other) treatments no less than patients without schizophrenia. All patients, regardless of whether diagnosed with schizophrenia or not, should receive the same attention and same treatment from healthcare practitioners. Reducing such stigmatization can and should encourage more equitable and effective healthcare practices for individuals with schizophrenia, both in terms of the attitude from practitioners and the resource investment needed to provide the best available care. In the case of hypothyroidism specifically, recent research points to the antipsychotic medications playing an important role in the etiology of the disorder (Melamed et al., 2020). Limitations This study has all the limitations inherent to a retrospective study design. In addition, the study group is of relatively small size. Some studies have found that thyroid function can be affected by early-life psychosocial factors such as childhood trauma. Early life is known to constitute a sensitive period for the long-term effects on the endocrine system, related to the functioning of the hypothalamic–pituitary–thyroid axis (Varese et al., 2012; Machado et al., 2015). However, neither Śmierciak et al. (2022) nor our study could find any reports explaining the dependencies or mechanisms of this relationship. Additionally, the present study showed no evidence of a relationship between sociodemographic and cultural factors and adherence to treatment, since both the study and the control group were matched for socioeconomic status and cultural background. A future study should investigate the impact of social and cultural backgrounds, healthcare systems and their policies on treatment adherence in patients with schizophrenia. Longitudinal cohort studies are needed to clarify long-term health outcomes associated with treatment adherence or non-adherence in patients with comorbid schizophrenia and how they vary on an international scale. Such studies should also identify the effective strategies to improve adherence in psychiatric patients. Conclusion To the best of our knowledge, this is the first study to address the subject of adherence to hypothyroidism treatment in patients with schizophrenia. Our results boost those of previous studies of adherence in patients with schizophrenia and should help destigmatize the perception of non-adherence as a trait of schizophrenia and the unjustified blaming of these patients as being responsible for the under-treatment they receive. To Prof. Gary Belkin Editor-In-Chief Cambridge Prisms: Global Mental Health Dear Prof. Belkin, We hereby re-submit our manuscript entitled: “Adherence of patients with schizophrenia to hypothyroidism treatment” for publication in your journal. This is an original study that used an electronic medical database to compare adherence to hypothyroidism treatment of patients with schizophrenia to the adherence to such treatment of patients without schizophrenia. The results indicate that, contrary to often held opinions, patients with schizophrenia adhere to hypothyroidism treatment no less than patients without schizophrenia. All the authors of this article had access to all study data, are responsible for all contents of the article, and had authority over manuscript preparation and the decision to submit the manuscript for publication. All listed authors gave their approval to the submission of the manuscript to this journal. The authors know of no other published, submitted or proposed papers reporting the same or overlapping data. None of the authors reports any financial or other conflict of interest with regard to this study. We hope that you will find this article suitable for publication in your journal. Sincerely, Dr. Shay Gur MD On behalf of the authors This is an important and unbiased retrospective study that interrogated a large health system database to identify two groups of patients with hypothyroidism: those with and without a comorbid diagnosis of schizophrenia. The data show that the patients with schizophrenia did not differ from those without schizophrenia in terms of adherence to treatment and treatment monitoring. The data have important public health implications for the management of schizophrenia, encouraging physicians to address this frequent comorbid condition. I am certain the investigators will explore possible psychiatric implications of poor adherence to maintenance of a euthyroid state in what may be a minority of schizophrenia patients with a comorbid diagnosis of hypothyroidism. The authors may wish to address the discrepancy between the 121 patients with schizophrenia and coexisting hypothyroidism and the 190 patients with a diagnosis of hypothyroidism presented in the Methods, which conflicts with the number of patients presented in the Abstract and analyzed in the Results. Dear all, Thank you for the opportunity to review this manuscript. This is a relevant paper examining adherence to hypothyroidism treatment in patients with comorbid schizophrenia, comparing them to a control group without schizophrenia. The study shows strengths when addressing and acknowledging the important topic of the stigma associated with clinicians in the field regarding patients with schizophrenia and their adherence to treatment. Another strength of the paper is the objective measures it employs providing a comprehensive view of treatment adherence. The study makes a clear and important conclusion that adherence to medication of patients with schizophrenia was “found to be as good as that of individuals without a schizophrenia diagnosis.” The study’s results are direct and useful for healthcare providers. However, I believe the study can greatly benefit by further showing how the study’s results specifically fit within the context of global research and how they can inform healthcare practices. The manuscript could include the following elements: Provide a more extensive review of the literature on treatment adherence in patients with comorbid schizophrenia and hypothyroidism, clearly including and depicting an array of literature around the world. Discussing findings from multiple countries to establish the global context. Further development of this point, the study could include statistics on the global prevalence of schizophrenia and hypothyroidism, and compare these rates across countries to underline any potential variations in morbidity and treatment adherence. Additionally, the study can include sociodemographic and cultural factors, and pinpoint how these factors might vary. To make the study fit the global health context the study can investigate the impact of different healthcare systems and their policies to treatment adherence in patients with schizophrenia. Compare and contrast various countries in the context of effective strategies to improve adherence in psychiatric patients. I also believe the study would benefit significantly from discussing the long-term health outcomes associated with treatment adherence or non-adherence in patients with comorbid schizophrenia, and how they vary on an international scale. As mentioned above, the study shows strengths when giving light to the important topic of the stigma associated with clinicians in the field regarding patients with schizophrenia and their adherence to treatment. This stigma can influence the way clinicians interact with and treat these patients. Using the evidence provided, the study should clearly depict how reducing such stigmatization can and should encourage more equitable and effective healthcare practices for individuals with schizophrenia. On a different point, the study provides a simple overview of how the participants were included but lacks specific details about how the inclusion criteria was confirmed, and the process of selecting participants. Specifically, there is little clarity as to how the control group was selected. The study mentions that the control group was matched to the schizophrenia group within the factors of age, gender, and socioeconomic status, but it is unclear how this process was conducted. Furthermore, the study does not mention whether or not there was an exclusion criteria used, if so it should be noted. Lastly, pertaining to the statistical analysis and results, I think data validation is critical, and the study should mention the steps taken to validate the accuracy of the diagnoses, medication records for all participants, as well as Student’s t-test used to calculate the differences between the groups. Overall, I believe that the authors did a good job with the paper, talking about an important topic within the world of schizophrenia. No accompanying comment. No accompanying comment. Nov. 5, 23 To Dr Franco Mascayano Handling Editor Cambridge Prisms: Global Mental Health Dear Dr Mascayano, We hereby submit our revised manuscript entitled: “Adherence of patients with schizophrenia to hypothyroidism treatment”. The manuscript has been revised according to all your and the reviewers’ comments. Our detailed responses follow below. We hope that you will now find the manuscript suitable for publication. Sincerely, Dr. Shay Gur MD On behalf of the authors Authors’ Detailed Responses Handling Editor: Mascayano, Franco Please also ensure your manuscript complies with the following formatting points (a copy of our author guidelines is included for reference): Comments - Please include the abstract in the main text document. Response: Done - Please include an Impact Statement below the abstract (max. 300 words). This must not be a repetition of the abstract but a plain worded summary of the wider impact of the article. Response: Done - Submission of graphical abstracts is encouraged for all articles to help promote their impact online. A Graphical Abstract is a single image that summarises the main findings of a paper, allowing readers to quickly gain an overview and understanding of your work. Ideally, the graphical abstract should be created independently of the figures already in the paper, but it could include a (simplified version of) an existing figure or a combination thereof. Graphical abstracts should not be too text-heavy in order to be easily viewable at thumbnail size. If you do not wish to include a graphical abstract please let me know. Response: This is a case-control study which will not benefit from a graphical abstract. - Please ensure references are correctly formatted. In text citations should follow the author and year style. When an article cited has three or more authors the style ‘Smith et al. 2013’ should be used on all occasions. At the end of the article, references should first be listed alphabetically, with a full title of each article, and the first and last pages. Journal titles should be given in full. Response: Done - Statements of the following are required in the main text document at the end of all articles: ‘Author Contribution Statement’, ‘Financial Support’, ‘Conflict of Interest Statement’, ‘Ethics statement’ (if appropriate), ‘Data Availability Statement’. Please see the author guidelines for further information. Response: Done - Please submit figures as separate files and please ensure all files are submitted in an editable electronic format. Response: There are no figures in this manuscript. Reviewer(s)' Comments to Author: Reviewer: 1 Comments to the Author This is an important and unbiased retrospective study that interrogated a large health system database to identify two groups of patients with hypothyroidism: those with and without a comorbid diagnosis of schizophrenia. The data show that the patients with schizophrenia did not differ from those without schizophrenia in terms of adherence to treatment and treatment monitoring. The data have important public health implications for the management of schizophrenia, encouraging physicians to address this frequent comorbid condition. I am certain the investigators will explore possible psychiatric implications of poor adherence to maintenance of a euthyroid state in what may be a minority of schizophrenia patients with a comorbid diagnosis of hypothyroidism. Response: We thank the reviewer for his or her positive comments. The authors may wish to address the discrepancy between the 121 patients with schizophrenia and coexisting hypothyroidism and the 190 patients with a diagnosis of hypothyroidism presented in the Methods, which conflicts with the number of patients presented in the Abstract and analyzed in the Results. Response: We thank the reviewer for his or her attention. The discrepancy has now been corrected. Reviewer: 2 Comments to the Author Dear all, Thank you for the opportunity to review this manuscript. This is a relevant paper examining adherence to hypothyroidism treatment in patients with comorbid schizophrenia, comparing them to a control group without schizophrenia. The study shows strengths when addressing and acknowledging the important topic of the stigma associated with clinicians in the field regarding patients with schizophrenia and their adherence to treatment. Another strength of the paper is the objective measures it employs providing a comprehensive view of treatment adherence. The study makes a clear and important conclusion that adherence to medication of patients with schizophrenia was “found to be as good as that of individuals without a schizophrenia diagnosis.” The study’s results are direct and useful for healthcare providers. Response: We thank the reviewer for the positive and encouraging comments. However, I believe the study can greatly benefit by further showing how the study’s results specifically fit within the context of global research and how they can inform healthcare practices. The manuscript could include the following elements: Provide a more extensive review of the literature on treatment adherence in patients with comorbid schizophrenia and hypothyroidism, clearly including and depicting an array of literature around the world. Response: Unfortunately, there is no literature on treatment adherence in patients with comorbid schizophrenia and hypothyroidism. As indicated in the manuscript, our study seems to be the first one investigating this aspect. Discussing findings from multiple countries to establish the global context. Further development of this point, the study could include statistics on the global prevalence of schizophrenia and hypothyroidism and compare these rates across countries to underline any potential variations in morbidity and treatment adherence. Response: The manuscript now includes descriptions of findings world-wide on the various aspects of the association between schizophrenia and hypothyroidism. They were added just before the closing paragraph of the Introduction. Additionally, the study can include sociodemographic and cultural factors, and pinpoint how these factors might vary. To make the study fit the global health context the study can investigate the impact of different healthcare systems and their policies to treatment adherence in patients with schizophrenia. Compare and contrast various countries in the context of effective strategies to improve adherence in psychiatric patients. Response: A section on these topics was added to the Limitations section of the Discussion. I also believe the study would benefit significantly from discussing the long-term health outcomes associated with treatment adherence or non-adherence in patients with comorbid schizophrenia, and how they vary on an international scale. Response: This too was added to the Limitations section of the Discussion. As mentioned above, the study shows strengths when giving light to the important topic of the stigma associated with clinicians in the field regarding patients with schizophrenia and their adherence to treatment. This stigma can influence the way clinicians interact with and treat these patients. Using the evidence provided, the study should clearly depict how reducing such stigmatization can and should encourage more equitable and effective healthcare practices for individuals with schizophrenia. Response: The reviewer’s suggestion has been incorporated into the manuscript at the end of the one before last paragraph of the Discussion section. On a different point, the study provides a simple overview of how the participants were included but lacks specific details about how the inclusion criteria was confirmed, and the process of selecting participants. Specifically, there is little clarity as to how the control group was selected. The study mentions that the control group was matched to the schizophrenia group within the factors of age, gender, and socioeconomic status, but it is unclear how this process was conducted. Furthermore, the study does not mention whether or not there was an exclusion criteria used, if so it should be noted. Response: In the Methods section there is now a more detailed description of the selection of both, the study group and the controls, as well as exclusion criteria. Lastly, pertaining to the statistical analysis and results, I think data validation is critical, and the study should mention the steps taken to validate the accuracy of the diagnoses, medication records for all participants, as well as Student’s t-test used to calculate the differences between the groups. Response: Since the number of participants in this study was relatively small, data accuracy was validated by examining the data recorded in the medical files for each participant’s last visit. Regarding the differences between the groups, Student’s t-test was performed following accuracy validation. Overall, I believe that the authors did a good job with the paper, talking about an important topic within the world of schizophrenia. Response: Thank you. The authors have thoughtfully considered the critiques of the Reviewers in the preparation of their revision. The revised manuscript is acceptable for publication. No accompanying comment. No accompanying comment.